Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Intrinsic Value
Tibet Rhodiola Pharmaceutical Holding Co. engages in the manufacture and wholesale of pharmaceutical products. [ Read More ]
The intrinsic value of one Tibet Rhodiola Pharmaceutical Holding Co stock under the Base Case scenario is 88.66 CNY. Compared to the current market price of 44.77 CNY, Tibet Rhodiola Pharmaceutical Holding Co is Undervalued by 50%.
Valuation Backtest
Tibet Rhodiola Pharmaceutical Holding Co
Run backtest to discover the historical profit from buying and selling Tibet Rhodiola Pharmaceutical Holding Co stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Tibet Rhodiola Pharmaceutical Holding Co's business.
What risks and challenges
does Tibet Rhodiola Pharmaceutical Holding Co face in the near future?
Summarize the latest earnings report
of Tibet Rhodiola Pharmaceutical Holding Co.
Provide P/E
for Tibet Rhodiola Pharmaceutical Holding Co and its competitors.
Balance Sheet Decomposition
Tibet Rhodiola Pharmaceutical Holding Co
Current Assets | 3.5B |
Cash & Short-Term Investments | 2B |
Receivables | 895.6m |
Other Current Assets | 590.6m |
Non-Current Assets | 1.4B |
Long-Term Investments | 260.9m |
PP&E | 606.5m |
Intangibles | 425.5m |
Other Non-Current Assets | 78.1m |
Current Liabilities | 1.3B |
Accounts Payable | 43.2m |
Accrued Liabilities | 49.3m |
Short-Term Debt | 628.9m |
Other Current Liabilities | 598.2m |
Non-Current Liabilities | 65.6m |
Long-Term Debt | 1m |
Other Non-Current Liabilities | 64.6m |
Earnings Waterfall
Tibet Rhodiola Pharmaceutical Holding Co
Revenue
|
3B
CNY
|
Cost of Revenue
|
-186.5m
CNY
|
Gross Profit
|
2.8B
CNY
|
Operating Expenses
|
-1.9B
CNY
|
Operating Income
|
856.9m
CNY
|
Other Expenses
|
-74.5m
CNY
|
Net Income
|
782.4m
CNY
|
Free Cash Flow Analysis
Tibet Rhodiola Pharmaceutical Holding Co
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Tibet Rhodiola Pharmaceutical Holding Co's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
Score
Tibet Rhodiola Pharmaceutical Holding Co's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Tibet Rhodiola Pharmaceutical Holding Co's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
Tibet Rhodiola Pharmaceutical Holding Co's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Tibet Rhodiola Pharmaceutical Holding Co
According to Wall Street analysts, the average 1-year price target for Tibet Rhodiola Pharmaceutical Holding Co is 59.2 CNY .
Shareholder Return
Price
Tibet Rhodiola Pharmaceutical Holding Co
Average Annual Return | 34.16% |
Standard Deviation of Annual Returns | 115.08% |
Max Drawdown | -82% |
Market Capitalization | 11.1B CNY |
Shares Outstanding | 247 938 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Tibet Rhodiola Pharmaceutical Holding Co. engages in the manufacture and wholesale of pharmaceutical products. The company is headquartered in Lhasa, Xizang and currently employs 733 full-time employees. The firm operates its businesses through the distribution of proprietary drug products, as well as the processing of pharmaceuticals and others. The firm conducts its businesses primarily in South China, North China, East China, Central China and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Tibet Rhodiola Pharmaceutical Holding Co stock under the Base Case scenario is 88.66 CNY.
Compared to the current market price of 44.77 CNY, Tibet Rhodiola Pharmaceutical Holding Co is Undervalued by 50%.